LGM Pharma announces advanced analytical services
14 Mar 2024
Preview
Source: Pharmaceutical Technology
The advancement aims to provide a simplified and comprehensive solution for the manufacturing requirements of customers. Credit: Dmitry Kalinovsky / Shutterstock.com.
Contract development and manufacturing organisation (CDMO) LGM Pharma has announced a significant advancement of its analytical testing services.
In conjunction with the development, the CDMO increased capacity by 50% and invested $2m.
The enhancement bolsters its standalone offering and complements the launch of new suppository manufacturing expertise to its portfolio.
It aims to provide further internal bandwidth for boosting growth and offers a simplified and comprehensive solution for the manufacturing requirements of customers.
LGM Pharma has wide-ranging analytical testing capabilities for small-molecule drug substances and drug products and can cater to the needs of large and small clients, including established pharmaceutical enterprises and start-ups.
See Also:
Noramco launches North American pharma supply chain services provider
Preview
Source: Pharmaceutical Technology
A review of changing regulatory and analytical requirements of free amino acid monographs of the European Pharmacopoeia
Preview
Source: Pharmaceutical Technology
The CDMO also offers complete method development and validation services and stability testing, which includes real-time and expedited stability studies.
The analytical laboratories at the company’s facility in Irvine, California, US, feature advanced chromatography and spectroscopy instrumentation including inductively coupled plasma mass spectrometry and inductively coupled plasma optical emission spectrometry.
With a rising demand for suppositories, particularly in women’s health products, LGM Pharma will bolster its production capacity at its facility in Rosenburg, Texas.
Suppository drug delivery systems offer direct and effective drug absorption and precise drug release kinetics. They provide solutions for patients who have difficulty swallowing or have nausea, as well as for chronic conditions and women’s health.
LGM Pharma CEO Prasad Raje stated: “Offering standalone analytical testing expands our agility and capacity to serve as a strategic resource for our pharmaceutical partners, providing them with the flexibility to meet the precise needs of their expanding product portfolios.
“With our continuum of robust and tailored support services, we enable pharmaceutical companies to get to market faster and achieve sustainable success in today’s complex market.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.